Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Author:

Torres Sandra,Ortiz Cristina,Bachtler Nadine,Gu Wenyi,Grünewald Leon D.,Kraus Nico,Schierwagen Robert,Hieber Christoph,Meier Caroline,Tyc Olaf,Joseph Brol Maximilian,Uschner Frank Erhard,Nijmeijer Bart,Welsch Christoph,Berres Marie‐Luise,Garcia‐Ruiz Carmen,Fernandez‐Checa Jose Carlos,Trautwein Christian,Vogl Thomas J.,Zeuzem Stefan,Trebicka Jonel,Klein Sabine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hepatology

Reference37 articles.

1. Liver fibrosis;J Clin Invest,2005

2. Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population‐based study (2005 to 2018);Lancet Reg Health Eur,2021

3. Experimental liver fibrosis research: update on animal models, legal issues and translational aspects;Fibrogenesis Tissue Repair,2013

4. Extracellular matrix remodeling in chronic liver disease;Curr Tissue Microenviron Rep,2021

5. Angiotensin‐II type 1 receptor‐mediated Janus kinase 2 activation induces liver fibrosis;Hepatology,2014

Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3